NexXGEN Peptides LLC assumes no liability for improper handling, use, or distribution
Where is it registered
Throughout the global Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) trials, compared to all the other comparators once-weekly semaglutide displayed greater short-term efficacy, with more significant reductions in HbA 1c and multiple cardiometabolic benefits (including improving the control of blood pressure, blood lipids and body weight, among others) [14,15,16,17,18,19,20,21,22]
Lancet 366(9491):10591062
The compound's chemical identity is anchored by CAS registry number 170851-70-4 and PubChem CID 11338010